Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy

We report the case of a 43-year-old male patient with persistent multifocal, skin-restricted, CD30-positive, large T-cell lymphoma. Combination therapy of systemic interferon alfa and oral bexarotene was initiated on an experimental basis in the hope of circumventing therapies such as methotrexate,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2001-12, Vol.45 (6), p.914-918
Main Authors: French, Lars E., Shapiro, Michael, Junkins-Hopkins, Jacqueline M., Vittorio, Carmela C., Rook, Alain H.
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Anticarcinogenic Agents - administration & dosage
Antineoplastic agents
Antineoplastic Agents - administration & dosage
Biological and medical sciences
Drug Therapy, Combination
General aspects
Humans
Interferon-alpha - administration & dosage
Ki-1 Antigen - analysis
Lymphoma, T-Cell, Cutaneous - drug therapy
Lymphoma, T-Cell, Cutaneous - pathology
Male
Medical sciences
Pharmacology. Drug treatments
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
Tetrahydronaphthalenes - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the case of a 43-year-old male patient with persistent multifocal, skin-restricted, CD30-positive, large T-cell lymphoma. Combination therapy of systemic interferon alfa and oral bexarotene was initiated on an experimental basis in the hope of circumventing therapies such as methotrexate, radiotherapy, or multiple-agent chemotherapy that may be required in such cases. This treatment was associated with rapid and marked regression of the patient's cutaneous lesions. (J Am Acad Dermatol 2001;45:914-8.)
ISSN:0190-9622
1097-6787
DOI:10.1067/mjd.2001.117519